Fibrinolytic once daily

ApprovedSmall molecule

UUniversity of North Carolina, Chapel Hill

Fibrinolytic once daily is one of 6 small molecule programs targeting Empyema. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EmpyemaActive, not recruiting

EmpyemaApproved

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Empyema

#DrugCompanyPhaseTrials

Betadine

BBecton, Dickinson and Company

Activase

1 3

Urokinase

Mmedac GmbH

Phase 3

1 4

Tpa

UUniversity of Florida

Phase 3

1 5

Fibrinolytic once daily

UUniversity of North Carolina, Chapel Hill

Approved

1 6

Dnase

TThe Hospital for Sick Children

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalNot yet recruiting

Empyema

NCT07095361

Clinical

Trials by Indication[1]

Empyema1 trial

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

Not yet recruiting·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT07095361·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fibrinolytic once daily. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fibrinolytic once daily compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fibrinolytic once daily. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of North Carolina, Chapel Hill

Fibrinolytic once daily

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Empyema1 trial

References

Drug Info

Quick Facts

Related News